Novartis AG
- Country
- π¨πSwitzerland
- Ownership
- Public, Private
- Established
- 1996-01-01
- Employees
- 76K
- Market Cap
- $242.6B
- Introduction
Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.
Cardiovascular Risk Evaluation in Clinical Practice in Metabolic Syndrome Patients
- Conditions
- Metabolic Syndrome
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2008-09-22
- Lead Sponsor
- Novartis
- Target Recruit Count
- 600
- Registration Number
- NCT00171548
- Locations
- π¨π
Novartis Pharmaceuticals, Basel, Switzerland
Study to Assess the Efficacy and Safety of Monthly Octreotide Intramuscular Injections in Patients With Proliferative Diabetic Retinopathy After Lasercoagulation This Study is Not Being Conducted in the United States.
- Conditions
- Proliferative Diabetic Retinopathy
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2008-08-12
- Lead Sponsor
- Novartis
- Target Recruit Count
- 17
- Registration Number
- NCT00170742
- Locations
- π¨π
Novartis, Basel, Switzerland
Assessment of the Effects of Tegaserod in the Management of Gastroesophageal Reflux Disease (GERD) in Patients With Incomplete Response to Proton Pump Inhibitors (PPIs).
- Conditions
- Gastroesophageal Reflux Disease (GERD)
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2008-01-28
- Lead Sponsor
- Novartis
- Target Recruit Count
- 54
- Registration Number
- NCT00171418
- Locations
- πΊπΈ
Drug Research Services, Inc, Metairie, Louisiana, United States
πΊπΈThe Oklahoma Foundation for Digestive Research, Oklahoma City, Oklahoma, United States
Assessment of the Role of Tegaserod Therapy in the Management of Gastroesophageal Reflux Disease (GERD) Symptoms in Patients With Incomplete Response to Proton Pump Inhibitors (PPIs).
- Conditions
- Gastroesophageal Reflux Disease (GERD)
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2008-01-28
- Lead Sponsor
- Novartis
- Target Recruit Count
- 30
- Registration Number
- NCT00171483
- Locations
- πΊπΈ
Consultants for Clinical Research of South Florida, Boynton Beach, Florida, United States
πΊπΈMiami Research Associates, Miami, Florida, United States
πΊπΈUniversity Clinical Research, Pembroke Pines, Florida, United States
A 12-Week Study to Evaluate the Efficacy of Darifenacin to Increase the Warning Time in Patients With Overactive Bladder.
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2008-01-23
- Lead Sponsor
- Novartis
- Target Recruit Count
- 445
- Registration Number
- NCT00171145
- Locations
- πΊπΈ
Novartis, East Hanover, New Jersey, United States
Cognitive Effects of Darifenacin and Oxybutynin Extended Release in Volunteers Aged 60 and Over
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2008-01-23
- Lead Sponsor
- Novartis
- Target Recruit Count
- 150
- Registration Number
- NCT00170768
- Locations
- πΊπΈ
Washington Neuropsychological Institute LLC Georgetown, Washington, District of Columbia, United States
Clinical Study to Evaluate the Tolerability, Safety and Efficacy of Enteric-coated Mycophenolate Sodium, After Equimolar Conversion From Mycophenolate Mofetil (MMF), in Patients With Stable Renal Transplant Receiving Tacrolimus
- Conditions
- Prevention of Acute Rejection After Kidney Transplantation
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2011-02-02
- Lead Sponsor
- Novartis
- Target Recruit Count
- 132
- Registration Number
- NCT00171392
Clinical Study to Evaluate the Tolerability, Safety and Efficacy of Enteric-coated Mycophenolate Sodium After Equimolar Conversion From Mycophenolate Mofetil (MMF) in Patients With Renal Transplant
- Conditions
- Prevention of Acute Rejection After Kidney Transplantation
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2011-02-02
- Lead Sponsor
- Novartis
- Target Recruit Count
- 162
- Registration Number
- NCT00171379
Conversion From Tacrolimus to Cyclosporine Microemulsion in Liver Transplant Patients With New Onset Diabetes After the 3rd Month Post-transplant
- Conditions
- Maintenance Liver Transplant Patients With New Onset Diabetes
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2011-02-01
- Lead Sponsor
- Novartis
- Target Recruit Count
- 39
- Registration Number
- NCT00171717
Efficacy and Safety of Cyclosporine Microemulsion Given Once a Day in Adult Stable Liver Transplant Recipients
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2011-02-01
- Lead Sponsor
- Novartis
- Target Recruit Count
- 61
- Registration Number
- NCT00171509